default author photo

Changlu Hu

Anhui Provincial Cancer Hospital

Hefei

China

SCHOLARLY PAPERS

2

DOWNLOADS

124

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study

Number of pages: 33 Posted: 22 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Guangdong Pharmaceutical University - Department of Medical Oncology, Sichuan University - Collaborative Innovation Center for Biotherapy, Guangxi Medical University - Department of Respiratory Oncology, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Fujian Medical University - Department of Radiation Oncology, Fujian Medical University - Department of Radiation Oncology, Yue Bei People's Hospital - Department of Oncology Radiotherapy, Zhejiang University - Department of Medical Oncology, Nantong Tumor Hospital - Department of Oncology Radiotherapy, Chongqing Medical University - First Affiliated Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Head and neck surgery, Guangzhou University of Chinese Medicine - Department of Oncology, Fujian Medical University - Department of Radiation Oncology, Zhengzhou University - Henan Cancer Hospital, Liuzhou Worker’s Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Anhui Provincial Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Guangdong Medical University - Department of Oncology, Fudan University - Internal Medicine Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University - Department of Medical Oncology, Huazhong University of Science and Technology - Department of Oncology, Hebei Medical University - Fourth Hospital, Harbin Medical University - Department of Medical Breast oncology, Nanjing Medical University - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Department of Radiation Oncology, Guizhou Medical University (Guiyang Medical University) - Department of Head and Neck oncology, Haikou People’s Hospital - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Tianjin Medical University - Department of Oncology Radiotherapy, Jilin University (JLU) - Cancer Center, Huazhong University of Science and Technology - Cancer Center, Wenzhou Medical University - Department of Medical Oncology, Yunnan Cancer Hospital, Central South University - Department of Oncology, Central South University - Department of Oncology, Shandong University - Department of Head and Neck neoplasm, Dalian University - Department of Oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Downloads 71 (867,774)

Abstract:

Loading...

KL-A167, nasopharyngeal carcinoma, efficacy, safety, PD-L1, biomarker

2.

Efficacy and Safety of Envafolimab, Suvemcitug and Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer: An Open-Label Phase Ii Clinical Trial

Number of pages: 24 Posted: 10 Jan 2025
Jilin Cancer Hospital - Department of Oncology, Jilin Cancer Hospital, Zhengzhou University - Henan Provincial People's Hospital, Shandong Provincial Cancer Hospital, affiliation not provided to SSRN, The First Affiliated Hospital of Zhengzhou University, affiliation not provided to SSRN, Anhui Medical University, affiliation not provided to SSRN, Anhui Provincial Cancer Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 53 (1,041,696)

Abstract:

Loading...

Non-small cell lung cancer, Suvemcitug, Anti-angiogenesis, Envafolimab, immune checkpoint inhibitor